Ghana’s Milestone in Reducing Child Malaria Deaths

Ghana has made remarkable strides in reducing child malaria deaths, thanks in part to the introduction of two new vaccines. This achievement, as noted by Gavi, the international vaccine aid group, underscores the potential of the vaccines to combat a disease that claims nearly half a million young lives each year in Africa.

However, concerns loom large. Cuts in aid from the Trump administration and other wealthy nations could result in fewer children benefiting from these vaccines across Africa, Gavi has indicated.

Ghana had already been successfully decreasing malaria mortality through measures such as distributing insecticide-treated bed nets and improving access to both preventive medications and effective treatment.

According to Dr. Selorm Kutsoati, who leads Ghana’s immunization program, the new vaccines—one from British firm GSK and another from Oxford University in partnership with the Serum Institute of India—are pivotal in closing the remaining gaps in malaria prevention.

These vaccines have been implemented in 24 African countries with Gavi’s support, despite initial skepticism from major global organizations regarding their effectiveness. The World Health Organization (WHO) has reported that clinical trials indicate these vaccines reduce malaria cases by over 50% in the first year after three doses, although these rates are lower than many traditional childhood vaccines.

In Ghana, child mortality rates related to malaria have plummeted—86% from 245 deaths in 2018 to just 35 in 2024, according to government statistics. Simultaneously, malaria infections decreased from around 6.7 million to 5.3 million during the same period. However, it’s worth noting that actual numbers may be higher, since many cases go undiagnosed and some deaths in homes often go unreported.

Esther Kolan, a mother from Kasoa, was determined to vaccinate her son Phenehas after losing her brother to malaria. “I have to go for the vaccine,” she said, emphasizing the importance of preventive measures. Her son has received all three doses without requiring hospitalization for malaria.

Yet, challenges remain. While some regions have managed to eliminate malaria without vaccines, sub-Saharan Africa still struggles due to various factors, including poverty, weak healthcare systems, and increasingly resistant disease strains. Gavi’s funding has come under pressure, with the organization anticipating a budget shortfall of $800 million over the next five years, which could jeopardize vaccination efforts and result in an estimated loss of 19,000 lives.

Additionally, the U.S. plans to withdraw support from Gavi unless certain vaccine preservatives are phased out, which has raised concerns about the future of funding for these vital programs.

Despite these obstacles, some countries are making strides to cover their own vaccine needs, and upcoming price reductions for malaria vaccines might help alleviate some financial burdens. GSK is expected to lower the vaccine cost to under $5 per dose by 2028, which could facilitate wider access.

Overall, while Ghana’s efforts show promise, the future depends heavily on sustained support and effective resource allocation to continue this critical fight against malaria.